Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut.

Trial Profile

Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Octreotide (Primary)
  • Indications Neuroendocrine carcinoma; Neuroendocrine tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms PROMID
  • Most Recent Events

    • 04 Jun 2013 Overall survival results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top